Anosmia
53
6
9
26
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
3.8%
2 terminated out of 53 trials
92.9%
+6.4% vs benchmark
15%
8 trials in Phase 3/4
31%
8 of 26 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 26 completed trials
Clinical Trials (53)
Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional MRI (fMRI), and Diffusion-Weighted Imaging (DWI)
Slow-SPEED UK: A Double-Blind Randomised Feasibility Trial
Scents of Progress: Leveraging a Novel Device for Olfactory Training in Older Adults
Multimodal Chewing Gum Flavour Training to Aid Flavour Perception Recovery - a Pilot Study.
Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2
Chemosensory Dysfunction and Recovery in Endoscopic Endonasal Skull Base Surgery
Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction
Intranasal Platelet-Rich Plasma With or Without Topical Insulin for Post-Inflammatory Anosmia
Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity
Topical Versus Injection PRP for Olfactory Dysfunction
Assessment of Olfactory Dysfunction in SARS CoV-2 (COVID-19) Infection
Olfactory Training on Smell Dysfunction Patients in HK
Efficacy of Platelet-rich Plasma in Management of Anosmia
Theophylline Nasal Spray for PD-Related Hyposmia and Anosmia
Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction
Sodium Citrate in Smell Retraining for People With Post-COVID-19 Olfactory Dysfunction
Investigating the Efficacy of OMT to Recover Olfactory Perception After COVID-19
Olfactory Training As a Treatment for Olfactory Dysfunction Post COVID-19
Characteristics of the Anosmic Olfactory Mucosa
Treatment of Pediatric Patients That Lost Sense of Smell Due to COVID-19